Sarepta Therapeutics Inc. (SRPT) Given “Outperform” Rating at Oppenheimer Holdings Inc.
Oppenheimer Holdings Inc. restated their outperform rating on shares of Sarepta Therapeutics Inc. (NASDAQ:SRPT) in a report issued on Sunday morning. They currently have a $76.00 target price on the stock.
Several other research firms have also recently weighed in on SRPT. RBC Capital Markets upgraded shares of Sarepta Therapeutics from a sector perform rating to an outperform rating in a research report on Monday, September 19th. William Blair reiterated a market perform rating on shares of Sarepta Therapeutics in a research report on Monday, June 27th. Needham & Company LLC increased their price objective on shares of Sarepta Therapeutics from $20.00 to $26.00 and gave the stock a buy rating in a research report on Friday, July 22nd. WBB Securities reiterated a strong-buy rating and set a $60.00 price objective (up from $40.00) on shares of Sarepta Therapeutics in a research report on Tuesday, September 20th. Finally, Robert W. Baird reiterated an outperform rating and set a $102.00 price objective on shares of Sarepta Therapeutics in a research report on Friday. One analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $54.44.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.71% during midday trading on Friday, reaching $61.41. 2,507,794 shares of the company’s stock traded hands. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The stock has a 50 day moving average of $35.91 and a 200-day moving average of $23.83. The stock’s market cap is $2.94 billion.
Sarepta Therapeutics (NASDAQ:SRPT) last posted its quarterly earnings data on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.19) by $0.16. During the same period in the prior year, the business posted ($0.87) EPS. On average, equities research analysts forecast that Sarepta Therapeutics will post ($4.16) EPS for the current fiscal year.
In related news, SVP David T. Howton sold 7,000 shares of the company’s stock in a transaction on Thursday, September 22nd. The shares were sold at an average price of $60.00, for a total transaction of $420,000.00. Following the completion of the sale, the senior vice president now directly owns 28,453 shares in the company, valued at approximately $1,707,180. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, VP Jayant Aphale sold 35,000 shares of the company’s stock in a transaction on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the sale, the vice president now owns 21,490 shares of the company’s stock, valued at $1,074,500. The disclosure for this sale can be found here. Corporate insiders own 10.90% of the company’s stock.
Large investors have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its stake in Sarepta Therapeutics by 13.6% in the second quarter. Teacher Retirement System of Texas now owns 6,034 shares of the company’s stock worth $115,000 after buying an additional 724 shares in the last quarter. Advisor Group Inc. purchased a new stake in Sarepta Therapeutics during the second quarter worth approximately $154,000. Quantitative Systematic Strategies LLC purchased a new stake in Sarepta Therapeutics during the second quarter worth approximately $211,000. National Planning Corp raised its stake in Sarepta Therapeutics by 2.1% in the first quarter. National Planning Corp now owns 13,678 shares of the company’s stock worth $242,000 after buying an additional 275 shares in the last quarter. Finally, First Allied Advisory Services Inc. raised its stake in Sarepta Therapeutics by 6.7% in the second quarter. First Allied Advisory Services Inc. now owns 12,800 shares of the company’s stock worth $245,000 after buying an additional 800 shares in the last quarter. Institutional investors own 72.09% of the company’s stock.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Stock Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related stocks with our FREE daily email newsletter.